GEN Exclusives

More »

GEN News Highlights

Back to Item »

Biogen Idec's Multiple Sclerosis Drug Meets All Endpoints in First Phase III Trial

Treatment with BG-12 led to significant reductions in relapse rate at two years.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Fear or Encouragement?

To change public attitudes about dealing with health issues do you agree that the public officials should rely on fear and disgust instead of encouraging and promoting healthy behaviors?

More »